Optimized Bexarotene Aerosol Formulation Inhibits Major Subtypes of Lung Cancer in Mice

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Bexarotene inhibits tumorigenesis but oral administration causes hyperlipidemia.
• Aerosolized bexarotene showed chemopreventive activity in lung adenoma models without hypertriglyceridemia.

Purpose of the Study:

• To develop and test a clinically relevant aerosolized bexarotene formulation for lung cancer prevention.
• To evaluate the efficacy and safety of optimized aerosolized bexarotene against major lung cancer subtypes.

Main Methods:

• Formulation of aerosolized bexarotene with a clinically relevant solvent system.
• Testing the optimized formulation in mouse models of lung squamous cell carcinoma and lung adenocarcinoma.
• Assessing toxicity, plasma lipid levels, drug distribution, and immune response (T cell population).
• RNA sequencing to identify altered molecular pathways in lung cancer cell lines.

Main Results:

• The optimized aerosolized bexarotene demonstrated significant chemopreventive effects in both lung cancer models.
• No visible toxicity or increase in plasma triglycerides or cholesterol was observed.
• Even distribution in lung parenchyma and increased tumor-infiltrating T cells were noted.
• Bexarotene modulated multiple molecular pathways in lung cancer cells.

Conclusions:

• A novel, clinically relevant aerosolized bexarotene formulation is effective in preventing major lung cancer subtypes.
• This aerosolized delivery method offers a promising advancement for lung cancer prevention in high-risk populations.
• The formulation modulates the tumor microenvironment, enhancing anti-tumor immunity.